Andrew A. Ortiz

Repurposed therapeutics in alzheimer’s disease: a comparative analysis of generic and patent-protected agents (2016–2025)

Repurposing approved drugs for Alzheimer’s disease (AD) offers a cost-effective strategy to accelerate therapeutic development. This study characterizes the role of repurposed agents in the 2025 AD drug development pipeline. Data was obtained from clinicaltrials.gov using an auto...